SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

OPK-8801001

OPK·OPKO HEALTH, INC.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Phase 1/2a
Time to market
At least 5-7 years, assuming successful completion of Phase 1/2a, Phase 2, and Phase 3 trials followed by regulatory filing and review.
Why 2/10
No hard, dated catalyst is scheduled in the next ~12 months. The Phase 1/2a trial just began dosing on October 27, 2026, and initial data readout is likely years away. This is a very early-stage program at a diversified company with approved products, so impactScore is low.
Actionable Insight NEUTRAL

OPK-8801001 just began Phase 1/2a dosing on October 27, 2026, so the next meaningful catalyst is initial safety and pharmacodynamic data, likely not for 12+ months. For OPKO Health, the bigger near-term drivers are the Labcorp/BioReference asset sale closing and NGENLA royalty revenue trends. This early-stage program is unlikely to move the stock in the foreseeable future.

Price Chart

Loading chart...

Executive Summary

OPK-8801001 is an investigational long-acting human growth hormone receptor antagonist being developed by OPKO Health (NASDAQ: OPK) for acromegaly, a rare endocrine disorder. The drug aims to be a once-weekly injectable alternative to the current daily standard-of-care pegvisomant (Somavert). On October 27, 2026, OPKO announced the first participant had been dosed in a first-in-human Phase 1/2a trial. Preclinical data presented at ENDO 2026 showed robust IGF-1 suppression and roughly 20-fold greater in vitro potency versus pegvisomant. However, the program is very early-stage (Phase 1/2a, just initiated) and represents a small part of OPKO Health's diversified business, which includes the approved product NGENLA (partnered with Pfizer), pharmaceutical sales in international markets, and a diagnostics business being sold to Labcorp. No near-term binary catalyst exists for this drug.

How It Works

OPK-8801001 is a growth hormone receptor antagonist. It blocks the receptor that growth hormone normally binds to, reducing the effects of excess growth hormone in the body. It is designed as a long-acting, once-weekly injection, in contrast to the current standard-of-care drug pegvisomant (Somavert), which requires daily injections.

Trial Status

First participant dosed on October 27, 2026, in a first-in-human Phase 1/2a study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamic activity (IGF-1 suppression). The trial is actively recruiting/enrolling. Preclinical data were presented at ENDO 2026 in June 2026.

The Two-Sided Case

▲ Bull Case4
Preclinical data presented at ENDO 2026 showed robust, dose-dependent, sustained IGF-1 suppression in animal models, and the drug reportedly has roughly 20-fold greater in vitro potency versus the standard-of-care pegvisomant.
OPK-8801001 targets a clear unmet need: a once-weekly injection versus the current daily pegvisomant regimen, which could improve patient compliance and capture market share.
OPKO Health has deep expertise in growth hormone biology through its approved product NGENLA (somatrogon, partnered with Pfizer), and its stabilizer-based technology platform is already clinically validated.
The global acromegaly treatment market is estimated at roughly $1.8 billion in 2025 and growing at 6-7% CAGR, providing a meaningful commercial opportunity if the drug succeeds.
▼ Bear Case4
Phase 1/2a trials have a high failure rate; the drug could fail on safety or fail to show adequate IGF-1 suppression in humans despite promising preclinical data.
The acromegaly market already has established therapies including daily pegvisomant (Somavert, Pfizer) and long-acting somatostatin analogs, creating a high bar for a new entrant.
OPK-8801001 is a very small program within OPKO Health's broader pipeline; even if successful, it is years from commercialization and unlikely to move the stock near-term.
The company reported a Q3 2026 net loss and is undergoing a major restructuring with the sale of its BioReference diagnostics business, creating execution risk.

Upcoming Catalysts

  • Initial Phase 1/2a safety and pharmacodynamic data readout (no date announced; likely 12+ months away)
  • Potential Phase 2/3 trial initiation (years away)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

OPKO HEALTH, INC. 8-K OPK ·Originating report

Sources · 8

Hover a chip for the title
1 opko.com2 opko.com3 opkobiologics.com4 peptideandprotein.com5 opko.com6 sec.gov7 opkobiologics.com8 verifiedmarketreports.com